Results for the financial for the quarter and nine months ended on 31st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences reported Q3 FY26 revenue of Rs 30.10 crore (Lakhs 3,010), nearly flat year-on-year versus Rs 30.10 crore in Q3 FY25, but down about 11% sequentially from Rs 34.00 crore in Q2 FY26. Nine-month revenue rose about 8.7% YoY to Rs 87.68 crore from Rs 80.68 crore. Net profit for Q3 jumped to Rs 5.44 crore from Rs 4.57 crore in Q3 FY25 (around 19% growth), helped by lower finance costs (Rs 74.86 lakh vs Rs 100.77 lakh) and lower employee expenses, though 9M FY26 PAT fell roughly 7% YoY to Rs 7.06 crore from Rs 7.62 crore. Basic EPS for Q3 was Rs 1.15 vs Rs 0.97 a year ago, and 9M EPS was Rs 1.49 vs Rs 1.61. The auditors (Neeraj Arora & Associates) gave a clean limited-review report with no qualifications. The board also approved re-appointment of Mr. Sameer Goel as Managing Director for another five years, subject to shareholder approval.
Mixed picture for shareholders: quarterly profitability improved on cost control but revenue is stagnant and nine-month earnings are slightly lower, suggesting margin pressure at the half-year level even as Q3 shows a recovery. The long-term re-appointment of the promoter-MD provides management continuity but does not by itself lift the near-term earnings outlook.